Table 2.

Patient, Tumor and Other Characteristics by Tumor Genotype

	EGFR mutation+	KRAS mutation+ ^		ALK translocation ^		EGFR WT/KRAS WT/ALK FISH negative
	(n=97)	(n=15)	p	(n=26)	p	(n=45)	p
Age (years)			0.627		0.011		0.168
Median (range)	57 (26–83)	61 (31–74)		47.5 (29–81)		54 (26–79)
Sex			0.135		0.092		0.327
Female	70 (72%)	8 (53%)		14 (54%)		29 (64%)
Male	26 (28%)	7 (47%)		12 (46%)		16 (36%)
Ethnicity			0.070*		0.781*		0.239*
White	71 (73%)	13 (86%)		19 (73%)		34 (76%)
Asian	19 (19%)	0 (0%)		4 (15%)		5 (11%)
Black	5 (5%)	1 (7%)		0 (0%)		4 (9%)
Hispanic/Other	2 (2%)	1 (7%)		3 (12%)		2 (4%)
Stage			<0.001		0.350		0.014
I–III	28 (29%)	12 (80%)		10 (38%)		23 (51%)
IV	69 (71%)	3 (20%)		16 (62%)		22 (49%)
Histology			0.378#		1.000#		0.410#
Adenocarcinoma	87 (90%)	12 (80%)		24 (92%)		38 (84%)
Squamous cell	2 (2%)	1 (7%)		0 (0%)		2 (4%)
Other	8 (8%)	2 (13%)		2 (8%)		5 (11%)
Family History
Any Cancer	53 (55%)	5 (33%)	0.167	19 (73%)	0.117	29 (64%)	0.361
Lung Cancer	22 (23%)	1 (7%)	0.300	3 (12%)	0.278	9 (20%)	0.829
Other Cancers	31 (32%)	4 (26%)	0.773	16 (62%)	0.011	20 (44%)	0.188

^*Asian versus non-Asian;

^#Adenocarcinoma versus non-adenocarcinoma

⁺ one patient with a tumor with EGFR mutation and KRAS mutation was excluded from analysis

^{^} one patient with a tumor with ALK translocation and KRAS mutation was excluded from analysis

EGFR, epidermal growth factor receptor; KRAS, V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog; ALK, anaplastic lymphoma kinase; FISH, fluorescence in situ hybridization